Company news
Abivax SA news in 2025
Abivax SA's news releases, calls and decks from 2025, newest first.
Abivax to be Added to Nasdaq Biotechnology Index
December 18, 2025
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 17, 2025
Abivax Presents Third Quarter 2025 Financial Results
December 15, 2025
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
November 3, 2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
October 6, 2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
October 5, 2025
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
September 23, 2025
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
September 12, 2025
Abivax Presents First Half 2025 Financial Results
September 8, 2025
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
August 11, 2025
Abivax Announces Closing of $747.5 Million Public Offering
July 28, 2025
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
July 25, 2025
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 24, 2025
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
July 24, 2025
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 24, 2025
Abivax Announces Launch of Public Offering
July 23, 2025
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
July 22, 2025
Abivax Announces Results of its June 6, 2025 Annual General Meeting
June 11, 2025
Abivax Presents First Quarter 2025 Financial Results
June 2, 2025
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
April 29, 2025
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
April 22, 2025
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
April 22, 2025